Archemix

Archemix, a biopharmaceutical company, is leading the development of aptamers as a new class of directed therapeutics for the prevention and treatment of chronic and acute disease. Archemix believes the unique properties of aptamers hold extraordinary potential in the fast-breaking world of drug discovery and development. Because of their unequaled specificity for their molecular targets, aptamers provide a promising alternative to conventional therapeutic approaches in a wide range of disease areas, including many of those currently addressed by protein-based therapeutics. Archemix is leveraging a dominant patent portfolio and proprietary technologies to create a novel class of therapeutics which encompass many of the benefits of small molecule drugs and biotherapeutics. In addition to the company's core aptamer generation technology, Archemix possesses strong expertise in both preclinical and clinical drug development.